Again, these results are aligned with the phase III ALCANZA trial in CD30-positive CTCL patients (ORR of 54.7%, CR of 17.2%) [19,24] and the data from the Spanish Primary Cutaneous Lymphoma Registry (ORR to retreatment of 54%, CR of 23%) [14], which provides evidence that BV can help to significantly improve the prognosis of these patients. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.